newsfilter
← Earnings
Earnings Releases·

Gain Therapeutics — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Net loss per share improved to $0.07 in Q3 2026 from $0.15 in Q3 2025, while total operating expenses for the nine-month period declined to $13.2 million from $14.2 million; cash and cash equivalents decreased to $11.7 million as of September 30, 2026, from $20.8 million at year-end 2025.
  • **Clinical Progress:** Phase 1b open-label data for rexaceract demonstrated stability in Parkinson's motor symptoms over 12 months with no new safety signals, validating the disease-modifying hypothesis.
  • **Future Outlook:** The Phase 2 clinical trial for rexaceract is expected to initiate in Q1 2027 following a protocol redesign in Q4 2026, with an initial therapeutic indication for GT-04686 targeted for selection in Q4 2026.
  • **Strategic Updates:** The company appointed Jeanette Weidner as Vice President, Finance, to support the next phase of development, while the lead Parkinson's program continues to receive funding from The Michael J. Fox Foundation and other partners.
Company
GAIN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology